Abstract
Hydroxyurea (HU, NH(2)CONHOH), or hydroxycarbamide, is a hydroxamic acid derivative used as a drug for anti-neoplasm and sickle-cell disease. In this study, HU was found to have antioxidant activities against 2,2-diphenyl-1-picrylhydrazyl (DPPH) and hydroxyl radicals and dose-dependent inhibitory activities against monoamine oxidase (MAO)-A, MAO-B, and semicarbazide-sensitive amine oxidase (SSAO) as compared to controls of clorgyline, deprenyl, and semicarbazide respectively. HU showed mixed-type, competitive-type, and competitive-type inhibition, respectively, with respect to substrates of MAO-A, MAO-B, and SSAO with apparent inhibition constants (Ki) of 19.46, 5.38, and 1.84 microM.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biphenyl Compounds / chemistry
-
Cattle
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Free Radical Scavengers / chemistry
-
Free Radical Scavengers / pharmacology*
-
Hydroxyl Radical / chemistry
-
Hydroxyurea / chemistry
-
Hydroxyurea / pharmacology*
-
Kinetics
-
Oxidoreductases Acting on CH-NH2 Group Donors / antagonists & inhibitors*
-
Oxidoreductases Acting on CH-NH2 Group Donors / metabolism
-
Picrates / chemistry
Substances
-
Biphenyl Compounds
-
Enzyme Inhibitors
-
Free Radical Scavengers
-
Picrates
-
Hydroxyl Radical
-
1,1-diphenyl-2-picrylhydrazyl
-
Oxidoreductases Acting on CH-NH2 Group Donors
-
Hydroxyurea